ONCY Earnings Prediction
The chart below shows how ONCY performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ONCY sees a -1.99% change in stock price 10 days leading up to the earnings, and a -8.00% change 10 days following the report. On the earnings day itself, the stock moves by +0.66%. This data can give you a slight idea of what to expect for the next quarter's release.
ONCY Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.12
-14.29%
20.00%
No Data Available
ONCY Earnings Analysis
Oncolytics Biotech, Inc. Common Shares Corporation (ONCY.O) Earnings Conference Call
Positive
Breast Cancer Study Results: In the third quarter of 2024, the BRACELET-1 breast cancer study reported final data showing substantial improvement compared to paclitaxel monotherapy in critical metrics like progression-free survival and overall survival rates.
Therapeutic Benefit of Pelareorep: The median progression-free survival nearly doubled from 6.4 months in the control arm to 12.1 months in the pelareorep arm, indicating a significant therapeutic benefit.
Survival Rate Improvement: The overall survival rate showed an approximate 14-month benefit, reinforcing the potential of pelareorep in treating HR+/HER2- metastatic breast cancer.
Strong Liquidity Position: The company reported $19.6 million in cash and cash equivalents as of September 30, 2024, demonstrating strong liquidity to support ongoing operations and development.
Cost Management Success: General and administrative expenses decreased to $3.1 million in Q3 2024 from $5.2 million in Q3 2023, reflecting effective cost management strategies.
Negative
Operating Cash Flow Comparison: Net cash used in operating activities for the nine months ended September 30, 2024 was $19.1 million compared to $22.3 million for the nine months ended September 30, 2023.
Working Capital Changes: The decrease reflects non-cash working capital changes, partly offset by higher net operating activities in 2024.
Administrative Expense Reduction: General and administrative expenses for the third quarter of 2024 were $3.1 million compared to $5.2 million for the third quarter of 2023.
Investor Relations Impact: The decrease was primarily due to lower investor relations activities and transaction costs that were part of our 2023 public offering.
R&D Expense Increase: Research and development expenses for the third quarter of 2024 were $6.8 million compared to $5.8 million for the third quarter of 2023.
ONCY FAQs
How does ONCY typically perform around its earnings report dates?
Is Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ONCY Earning Call Sentiment
Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ONCY.O
3.21%Positive
The earnings call summary reveals mixed signals. Basic financial performance shows slight improvement, but the lack of shareholder return plans and ongoing financial risks are concerning. Product development and market strategy are promising, with potential accelerated approval and a large market opportunity. However, regulatory and clinical trial risks remain significant, and management's hesitance in providing clear timelines raises uncertainties. These factors balance out to a neutral sentiment, suggesting a stock price movement within the -2% to 2% range over the next two weeks.